Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abemaciclib for NF1 Related Atypical Neurofibromas
NCT04750928Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Nov 2021
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
A Phase 2 trial of abemaciclib in neurofibromatosis type 1 (NF1), sponsored by National Cancer Institute. Started Nov 2021; status: recruiting.
02
Drugs
abemaciclib
03
Conditions
neurofibromatosis type 1 (NF1)
Beyond the preview
Go deeper on NCT04750928.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04750928.